

## Effects of dietary curcumin on growth, antioxidant capacity, fatty acid composition and expression of lipid metabolism-related genes of large yellow croaker fed a high-fat diet

Renlei Ji<sup>1</sup>, Xiaojun Xiang<sup>1</sup>, Xueshan Li<sup>1</sup>, Kangsen Mai<sup>1,2</sup> and Qinghui Ai<sup>1,2\*</sup>

<sup>1</sup>Key Laboratory of Aquaculture Nutrition and Feed (Ministry of Agriculture and Rural Affairs) & Key Laboratory of Mariculture (Ministry of Education), Fisheries College, Ocean University of China, Qingdao, Shandong 266003, People's Republic of China

<sup>2</sup>Laboratory for Marine Fisheries Science and Food Production Processes, Qingdao National Laboratory for Marine Science and Technology, Qingdao, Shandong 266237, People's Republic of China

(Submitted 7 July 2020 – Final revision received 19 September 2020 – Accepted 25 September 2020 – First published online 20 October 2020)

### Abstract

A 10-week feeding trial was conducted to investigate the effect of dietary curcumin (CC) on growth antioxidant responses, fatty acid composition, and expression of lipid metabolism-related genes of large yellow croaker fed a high-fat diet (HFD). Four diets (lipid level at 18 %) were formulated with different levels of curcumin (0, 0.02, 0.04 and 0.06 %). The best growth performance was found in the 0.04 % curcumin group, with the body and hepatic lipid levels lower than the control group (0 % CC). The content of TAG, total cholesterol and LDL-cholesterol was the least in the 0.06 % curcumin group. The lowest malondialdehyde and the highest superoxide dismutase, catalase and total antioxidant capacity were observed in the 0.04 % curcumin group. The 0.04 % curcumin group had higher expression of  $\Delta 6fad$ , *elov15* and *elov14* and showed higher hepatic *n-6* and *n-3* PUFA. Expression of *ppara*, *cpt1*, and *aco* was significantly increased, while expression of *sreb1* and *fas* was dramatically decreased in curcumin groups compared with the control group. Overall, 0.04 % curcumin supplementation could mitigate the negative effects caused by HFD and promote growth via reducing hepatic lipid deposition, improving antioxidant activity and increasing PUFA of large yellow croaker. To conclude, abnormal hepatic lipid deposition was probably due to increased fatty acid oxidation and reduced *de novo* synthesis of fatty acids.

**Key word:** Curcumin: Antioxidant capacity: PUFA: Lipid metabolism: Large yellow croaker

Abnormal hepatic lipid deposition, excessive TAG accumulation in the liver, is increasingly prevalent in the farmed fish, due to the wide use of high-fat diet (HFD) which has a cost-effective farming and protein-sparing effects<sup>(1)</sup>. Hepatocyte lesion and lower disease resistance are indicators of hepatic steatosis caused by abnormal hepatic lipid deposition, resulting in considerable losses in aquaculture<sup>(2,3)</sup>. Collectively, it is meaningful to study lipid metabolism and explore a way to mitigate the negative effects of hepatic steatosis in the farmed fish.

Curcumin (CC, commonly known as turmeric), a polyphenolic compound derived from the *Curcuma longa*, is well documented for its medicinal properties in Chinese and Indian medicine systems<sup>(4,5)</sup>. Its biological and pharmacological functions have been well confirmed, such as antioxidative<sup>(6)</sup>, anti-inflammatory<sup>(7)</sup> and antimicrobial<sup>(8)</sup>. Additionally, recent studies have found that CC could alleviate liver diseases<sup>(9,10)</sup> and CVD<sup>(11)</sup> by regulating lipid and cholesterol metabolism<sup>(10–13)</sup>. Meanwhile, CC plays a vital role in the obesity and metabolic diseases treatment through mediating

lipid metabolism and inflammatory responses<sup>(14–17)</sup>. Given the medicinal properties and healthy benefits of CC in mammals, CC has attracted significant attention to aquaculture. CC and its active molecule have been confirmed to exert positive effects on fish health and lipid metabolism, including hepatoprotective, anti-inflammatory, immunomodulatory, antioxidant and anti-stress<sup>(18–20)</sup>. In tilapia, 50 mg/kg CC remarkably improved growth performance and immunity<sup>(20)</sup>. Fish fed the diet supplemented with 5 g/kg CC showed significantly higher final body weight and antioxidant capacity in crucian carp<sup>(21)</sup>. Therefore, CC has the potential to mitigate the adverse effects caused by HFD in farmed fish. In addition, plant species-based additives have no or fewer residue concerns and the adverse effects on animal, human and environment health<sup>(20,22)</sup>, as potential growth and health promoter in aquaculture<sup>(23,24)</sup>.

Large yellow croaker (*Larimichthys crocea*), widely cultured in southeast China, is an important economical marine fish due to its delicious taste and high nutritional value<sup>(25)</sup>. Furthermore,

**Abbreviations:** *aco*, acyl-CoA oxidase; CAT, catalase; CC, curcumin; *cpt1*, carnitine palmitoyltransferase I; *elov14*, elongation of very long-chain fatty acids protein 4; *elov15*, elongation of very long-chain fatty acids protein 5;  $\Delta 6fad$ ,  $\Delta 6$  fatty acyl desaturase; *fas*, fatty acid synthase; HFD, high-fat diet; MDA, malondialdehyde; SOD, superoxide dismutase; *sreb1*, sterol-regulatory element-binding protein 1.

\* **Corresponding author:** Professor Qinghui Ai, fax +86 532 82031943, email [qh.ai@ouc.edu.cn](mailto:qh.ai@ouc.edu.cn)

lipid metabolisms among the large yellow croaker, other fish and mammals are similar, and large yellow croaker could be considered as an appropriate model for regulation of lipid metabolism in marine fish<sup>(3,26–28)</sup>. Thus, this study was to investigate the protective effects of CC against hepatic steatosis. The underlying mechanism of the beneficial effect of CC was also focused.

## Materials and methods

### Animal ethics

The present study was conducted in strict accordance with the Management Rule of Laboratory Animals (Chinese Order No. 676 of the State Council, revised 1 March 2017) and approved by the Institutional Animal Care and Use Committee of the Ocean University of China.

### Feed ingredients and diet formulation

Ingredients and nutrient composition of four experimental diets are shown in online Supplementary Table S1. Four isoproteic (43% crude protein) and isolipidic (18% crude lipid) diets were formulated to contain graded levels of CC (0, 0.02, 0.04 and 0.06%; Beijing Solarbio Technology Co. Ltd; concentration  $\geq$  95%) (online Supplementary Table S1). The diet (18% lipid content) without CC supplementation was the control diet. Previous studies have been confirmed that 18% lipid level diet had the negative impacts on large yellow croaker, resulting in abnormal hepatic lipid deposition and inflammatory response<sup>(3,29)</sup>.

Dietary ingredients were ground into fine powder through a 320  $\mu$ m mesh. All the ingredients were thoroughly blended first by hand and then by machine. After that, all ingredients were thoroughly mixed with oil mixture and water, respectively. The automatic fish granulator (F-26; South China University of Technology) was used to make pellets (4 mm  $\times$  5 mm and 5 mm  $\times$  5 mm). Pellets were dried for about 12 h in an oven at 55°C, placed in double plastic bags and stored at –20°C until the trial.

### Experimental procedure

Juvenile large yellow croaker was provided by the Fu Fa Aquatic Products Co. Ltd. Before the start, fish were reared in floating sea cages (2 m  $\times$  4 m  $\times$  2 m) and fed the control diet for 14 d to adapt to the experimental conditions and diets.

At the initiation, fish were starved for 24 h and weighed. The fish of similar sizes (15.92 (SEM 0.16) g) were distributed into twelve sea cages (1 m  $\times$  1 m  $\times$  2 m). Each diet was randomly allocated to three cages (sixty fish/each cage) and fed twice daily (05.00 and 17.00 hours) for 10 weeks. During the experiment, conditions were as followed: water temperature (26.5–31.0°C), salinity (32–36‰) and dissolved oxygen (approximately 7 mg/l).

### Sample collection

At the termination, fish were starved for 24 h and anaesthetised with MS222 (1:10 000; Sigma). The body weight and total number of fish in each cage were recorded for analyses of survival

rate, final body weight, weight gain and specific growth rate. Six fish (each cage) were collected to analyse whole-body composition. The wet weight of the body, liver and visceral of six fish (per cage) was measured to analyse morphometric parameters. Muscle and liver tissue (at least six fish/cage) were collected and mixed for fatty acid profile and lipid content analyses, respectively. The blood was obtained from the caudal vein by 1 ml syringes from ten fish (each cage) and placed to clot at 4°C for 6–8 h. The clot and residual blood cells were removed by centrifugation for 10 min (3500 r/min). The serum was placed at –80°C for later analysis of biochemical and antioxidant parameters. Liver tissue (nine fish/each cage) was collected and mixed in 1.5 ml RNA-free tubes and then were immediately frozen in liquid N<sub>2</sub> which were stored at –80°C for gene expression analyses.

### Proximate composition, fatty acid profile and curcumin analyses

Crude protein, crude lipid and moisture of the whole body and the diet were analysed following the procedures of the Association of Official Analytical Chemists (AOAC, 2005). Briefly, the moisture content was measured by drying to constant weight at 105°C for 6–8 h. The crude lipid and crude protein content (N  $\times$  6.25) were determined by the ether extraction using Soxhlet method and Kjeldahl method, respectively. Lipid contents of liver and muscle were extracted and measured by chloroform–methanol (v/v, 2:1) as previously described<sup>(30)</sup>.

The fatty acid profile of liver and muscle was determined using the previously described procedures<sup>(31)</sup> with some modification<sup>(27,32,33)</sup>. The liver and muscle tissues were freeze-dried in a lyophilized chamber (Alpha 1-4 LDplus; Christ). HP6890 gas chromatograph (Agilent Technologies Inc.) with the capillary column (007-CW; Hewlett Packard) and a flame ionization detector were used to identify and quantify fatty acid methyl esters.

CC was analysed using the previously described procedures<sup>(34)</sup> and National Standards of the People's Republic of China (GB1886.76-2015) with some modification. Liquid chromatographic conditions: Purospher C<sub>18</sub> column (4.6 mm  $\times$  250 mm, 5  $\mu$ m particle size; Merck Drugs & Biotechnology). The mobile phase was composed of acetonitrile–4% acetic acid (55:45, v/v) at a flow rate of 1.0 ml/min. The wavelength of the detection was at 324 nm. The column temperature was 35°C. The injection volume was 10  $\mu$ l.

### Serum parameters and antioxidant capacity analysis

Serum total cholesterol, TAG, LDL-cholesterol, HDL-cholesterol, alanine transaminase and aspartate transaminase were determined by the automatic biochemical analyzer (Mindry BS-180; Mindry).

Serum superoxide dismutase (SOD), catalase (CAT), total antioxidant capacity and malondialdehyde (MDA) were measured by a commercial kit (Nanjing Jiancheng Bio-Engineering Institute). SOD activity was measured by the xanthine/xanthine oxidase method based on the production of O<sup>2-</sup>, which oxidises hydroxylamine to form nitrites, appearing purplish red in the presence of chromogenic agents. The CAT decomposition of H<sub>2</sub>O<sub>2</sub> is quickly terminated by adding ammonium molybdate. The remaining



H<sub>2</sub>O<sub>2</sub> forms a yellow complex with ammonium molybdate, and its variation is measured at 405 nm to calculate the CAT activity. Total antioxidant capacity is determined by colourimetry, where antioxidant substances reduce Fe<sup>3+</sup> to Fe<sup>2+</sup>, and Fe<sup>2+</sup> and phenanthrene substances form stable complexes. MDA is determined by the thiobarbituric acid method, where MDA and thiobarbituric acid form a red product with a maximum absorbance value at 532 nm.

### Quantitative real-time PCR

Gene expression was determined by real-time reverse-transcriptase quantitative PCR according to the previous procedure<sup>(33)</sup>. Total RNA was extracted from the liver of large yellow croaker using a Trizol Reagent (Invitrogen). The quality of isolated RNA was measured spectrophotometrically (Nanodrop 2000; Thermo Fisher Scientific), and the integrity was determined on a 1.2% denaturing agarose gel. Then, RNA was reverse-transcribed to cDNA by a Prime Script-RT reagent Kit with gDNA Eraser (perfect real-time) (Takara). Reverse-transcriptase quantitative PCR was performed in a quantitative thermal cycler (CFX96™ Real-Time System; BIO-RAD). The amplification was performed in a total volume of 25 µl, containing 1 µl of each primer (10 µmol), 1 µl cDNA product, 12.5 µl SYBR-Premix ExTaqII (Takara) and 9.5 µl RNA-free water. The real-time PCR programme was as follows: 95°C for 2 min, followed by forty cycles of 95°C for 10 s, 58°C for 10 s and 72°C for 20 s. The primer sequences were obtained from previous paper<sup>(3,26,28,35)</sup> (online Supplementary Table S2). The amplification efficiencies of all genes were approximately equal and ranged from 94 to 105%. The mRNA levels were calculated using the 2<sup>-ΔΔt</sup> method<sup>(36)</sup>. Finally, data were expressed as fold change relative to the control group.

### Statistical analysis

SPSS 19.0 (SPSS) was used to analyse all data. Data are shown as mean values with their standard errors. The one-way ANOVA method was used to analyse all data. Statistical significance was set at *P* < 0.05 using Tukey's multiple range tests.

## Results

### Growth performance and survival rate

Final body weight, weight gain and specific growth rate in fish fed the diet with 0.04% CC were significantly higher than the control group (fish fed the HFD) (*P* < 0.05) (Table 3). There were no statistical differences in SR, hepato-somatic index and viscera-somatic index among treatment groups (*P* > 0.05) (Table 1).

### Whole-body composition and lipid deposition in liver and muscle

The lipid levels of the whole body and liver were dramatically affected by dietary CC (*P* < 0.05) (Table 2). Liver lipid content decreased dose-dependently with increased CC, where liver lipid levels of 0.04 and 0.06% CC groups were remarkably lower than the control group (*P* < 0.05). In the whole body, fish fed the diet with 0.04% CC had the lowest lipid content (*P* < 0.05). No significant differences were observed in crude protein, moisture and muscle lipid content among treatment groups (*P* > 0.05) (Table 2).

### Serum metabolite parameters

The levels of total cholesterol, TAG and LDL-cholesterol decreased dose-dependently with the increased CC (Fig. 1). Fish fed diets with 0.04 and 0.06% CC had markedly lower levels of LDL-cholesterol and TAG than the control group (*P* < 0.05) (Fig. 1), while HDL-cholesterol levels were significantly higher in fish fed the diet with 0.04% CC (*P* < 0.05) (Fig. 1). The activity of alanine transaminase and aspartate transaminase was significantly decreased in 0.04% CC group compared with the control group (*P* < 0.05) (Fig. 1).

### Antioxidant parameters

MDA content was remarkably lower in CC supplementation groups compared with the control group (*P* < 0.05) (Fig. 2); moreover, the lowest MDA was observed in fish fed the diet with 0.04% CC (*P* < 0.05). The activity of CAT and SOD was strikingly higher in CC groups than the control group. In addition, fish fed

**Table 1.** Growth response and survival of large yellow croaker fed diets with graded levels of curcumin level (*n* 3) (Mean values with their standard errors)

	Curcumin level (% dry weight)							
	0		0.02		0.04		0.06	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Initial body weight (g)	15.85	0.02	15.85	0.16	15.90	0.14	15.72	0.09
Final body weight (g)	35.59 <sup>a</sup>	0.66	35.36 <sup>a</sup>	2.70	38.11 <sup>b</sup>	2.38	35.71 <sup>a</sup>	1.91
WG (%) <sup>*</sup>	124.58 <sup>a</sup>	4.48	123.17 <sup>a</sup>	19.28	139.86 <sup>b</sup>	16.64	127.15 <sup>a,b</sup>	11.76
SGR (%/d) †	1.16 <sup>a</sup>	0.03	1.15 <sup>a</sup>	0.01	1.25 <sup>b</sup>	0.04	1.17 <sup>a,b</sup>	0.04
SR (%) ‡	86.67	1.67	88.89	0.96	85.00	1.67	86.11	2.55
HSI (%) §	3.31	0.25	2.81	0.30	3.18	0.21	2.95	0.56
VSI (%)	8.56	8.56	8.15	0.37	8.55	0.40	8.36	0.12

WG, weight gain; SGR, specific growth rate; SR, survival rate; HSI, hepato-somatic index; VSI, viscera-somatic index.

<sup>a,b</sup> Mean values within a row with the same superscript letters were not significantly different among dietary treatments by Tukey's test (*P* > 0.05).

<sup>\*</sup> WG (%) = 100 × (final weight – initial weight)/initial weight.

† SGR (%/d) = 100 × (Ln final weight – Ln initial weight)/experiment period.

‡ SR (%) = 100 × final number/initial number.

§ HSI (%) = 100 × liver weight/body weight.

|| VSI (%) = 100 × visceral weight/body weight.






**Table 2.** Effects of curcumin on whole body composition of large yellow croaker (*n* 3) (% wet weight) (Mean values with their standard errors)

Index	Curcumin level (% dry weight)							
	0		0.02		0.04		0.06	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Moisture (%)	72.22	1.62	72.11	0.79	71.46	0.31	71.84	0.64
Crude protein (%)	15.14	0.46	15.23	0.54	15.81	0.25	15.33	0.14
Crude lipid (%)	9.36 <sup>b</sup>	0.17	8.89 <sup>a,b</sup>	0.17	8.55 <sup>a</sup>	0.32	8.80 <sup>a,b</sup>	0.35
Liver lipid content (%)	40.70 <sup>c</sup>	0.71	39.24 <sup>b,c</sup>	0.93	37.80 <sup>b</sup>	0.73	35.01 <sup>a</sup>	0.83
Muscle lipid content (%)	9.65	0.70	9.41	0.26	9.24	0.43	9.11	0.28

<sup>a,b,c</sup> Mean values within a row with the same superscript letters were not significantly different among dietary treatments by Tukey's test ( $P > 0.05$ ).




**Fig. 1.** Serum biochemical indexes and enzyme activities. (A) TAG, (B) total cholesterol (TC), (C) LDL-cholesterol, (D) HDL-cholesterol, (E) alanine transaminase (ALT) and (F) aspartate transaminase (AST) of large yellow croaker fed experimental diets. Results are means with their standard errors (*n* 3). <sup>a,b,c</sup> Mean values with the same letters were not significantly different among dietary treatments by Tukey's test ( $P > 0.05$ ).

the diet with 0.04% CC had the highest activity of SOD and CAT ( $P < 0.05$ ) (Fig. 2). Similarly, fish fed diets with 0.04% and 0.06% CC had significantly higher total antioxidant capacity than the control group ( $P < 0.05$ ) (Fig. 2).

**Fatty acid profiles**

The ratio of hepatic SFA:C18:1*n*-9 decreased gradually with the increased CC. However, C20:4*n*-6, C20:5*n*-3, C22:6*n*-3, *n*-6 PUFA and *n*-3 PUFA increased dose-dependently when CC

increased (Table 3). In the liver, SFA and C18:1*n*-9 were significantly lower in 0.04% CC group than the control group ( $P < 0.05$ ). The C20:4*n*-6, C20:5*n*-3, C22:6*n*-3, *n*-3 PUFA, *n*-6 PUFA, *n*-3:*n*-6 PUFA and *n*-3 Lc-PUFA were markedly higher in fish fed the diet with 0.04% CC than the control group ( $P < 0.05$ ). There was an upward trend of C22:6*n*-3, *n*-3 PUFA, *n*-3:*n*-6 PUFA and *n*-3 Lc-PUFA in the muscle, and no significant differences were observed among treatment groups ( $P > 0.05$ ) (Table 4).



**Fig. 2.** Antioxidant parameters in serum: (A) malondialdehyde (MDA), (B) superoxide dismutase (SOD), (C) catalase (CAT) and (D) total antioxidant capacity (T-AOC) in serum of large yellow croaker fed experimental diets. Results are means with their standard errors (*n* 3). <sup>a,b,c,d</sup> Mean values with the same letters were not significantly different among dietary treatments by Tukey's test (*P* > 0.05).

**Table 3.** Fatty acid profiles (% total fatty acids) in the liver of large yellow croaker (*n* 3) (Mean values with their standard errors)

	Curcumin level (% dry weight)							
	0		0.02		0.04		0.06	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
14:00	2.98	0.11	3.09	0.09	3.12	0.04	3.29	0.33
16:00	16.97	0.78	16.57	0.69	15.83	0.38	16.72	0.34
18:00	5.80	0.61	4.97	0.03	4.70	0.61	5.31	0.34
20:00	1.18	0.05	1.14	0.05	1.16	0.03	1.16	0.08
∑SFA	26.93 <sup>b</sup>	0.36	25.77 <sup>a,b</sup>	0.74	24.80 <sup>a</sup>	0.92	26.48 <sup>b</sup>	0.46
16:1 <i>n</i> -7	7.85	0.35	7.91	0.18	7.83	0.06	8.11	0.37
18:1 <i>n</i> -9	20.32 <sup>b</sup>	0.86	19.83 <sup>a,b</sup>	0.29	19.05 <sup>a</sup>	0.22	19.39 <sup>a,b</sup>	0.15
∑MUFA	27.90	1.08	27.75	0.12	26.87	0.25	27.50	0.51
18:2 <i>n</i> -6	24.27	0.72	25.01	0.58	25.50	1.17	24.18	0.75
20:4 <i>n</i> -6	0.49 <sup>a</sup>	0.01	0.53 <sup>b</sup>	0.02	0.57 <sup>c</sup>	0.01	0.54 <sup>b,c</sup>	0.01
∑ <i>n</i> -6 PUFA	24.76	0.72	25.54	0.59	26.07	0.68	24.73	0.75
18:3 <i>n</i> -3	2.36	0.01	2.45	0.11	2.45	0.05	2.58	0.40
20:5 <i>n</i> -3	2.69 <sup>a</sup>	0.19	3.04 <sup>b</sup>	0.12	3.33 <sup>b</sup>	0.11	3.14 <sup>b</sup>	0.06
22:6 <i>n</i> -3	2.07 <sup>a</sup>	0.28	2.30 <sup>a,b</sup>	0.15	2.55 <sup>b</sup>	0.07	2.25 <sup>a,b</sup>	0.08
∑ <i>n</i> -3 PUFA	7.11 <sup>a</sup>	0.48	7.72 <sup>b</sup>	0.21	8.40 <sup>c</sup>	0.23	7.76 <sup>b</sup>	0.21
<i>n</i> -3: <i>n</i> -6 PUFA	0.29 <sup>a</sup>	0.29	0.30 <sup>a,b</sup>	0.01	0.32 <sup>b</sup>	0.01	0.31 <sup>b</sup>	0.01
∑ <i>n</i> -3 LC-PUFA	4.76 <sup>a</sup>	0.47	5.34 <sup>b</sup>	0.23	5.89 <sup>b</sup>	0.18	5.40 <sup>b</sup>	0.13

LC-PUFA, long-chain PUFA.

<sup>a,b,c</sup> Mean values within a row with the same superscript letters were not significantly different among dietary treatments by Tukey's test (*P* > 0.05).



**Table 4.** Fatty acid profiles (% total fatty acids) in the muscle of large yellow croaker (*n* 3) (Mean values with their standard errors)

	Curcumin level (% dry weight)							
	0		0.02		0.04		0.06	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
14:00	3.79	0.42	3.74	0.24	3.58	0.05	3.52	0.10
16:00	18.73	1.26	18.62	0.28	18.44	0.33	17.54	0.17
18:00	4.98	0.04	4.97	0.23	5.04	0.28	5.06	0.50
20:00	1.13	0.10	1.15	0.06	1.25	0.80	1.32	0.11
∑SFA	28.64	1.56	28.49	0.66	28.30	0.30	27.44	0.38
16:1 <i>n</i> -7	6.37	0.31	6.44	0.27	6.21	0.26	6.05	0.15
18:1 <i>n</i> -9	17.64	0.54	17.70	0.56	17.55	0.55	17.09	0.26
∑MUFA	24.01	0.74	24.13	0.67	23.76	0.81	23.14	0.11
18:2 <i>n</i> -6	23.78	0.54	22.54	1.45	22.61	1.17	22.15	0.81
20:4 <i>n</i> -6	0.66	0.02	0.72	0.04	0.73	0.02	0.70	0.08
∑ <i>n</i> -6 PUFA	24.44	0.53	23.26	1.44	23.35	1.19	22.86	0.84
18:3 <i>n</i> -3	2.35	0.10	2.33	0.03	2.27	0.03	2.26	0.18
20:5 <i>n</i> -3	4.02	0.37	4.40	0.13	4.26	0.16	4.34	0.17
22:6 <i>n</i> -3	3.59	0.29	4.00	0.39	4.26	0.16	4.14	0.28
∑ <i>n</i> -3 PUFA	9.79	0.68	10.72	0.50	10.79	0.23	10.75	0.49
<i>n</i> -3: <i>n</i> -6 PUFA	0.41	0.03	0.46	0.05	0.46	0.03	0.47	0.01
∑ <i>n</i> -3 LC-PUFA	7.61	0.63	8.40	0.52	8.52	0.25	8.49	0.37

LC-PUFA, long-chain PUFA.

### mRNA levels of genes related to lipid metabolism

The transcript levels of *ppara*, carnitine palmitoyltransferase I (*cpt1*) and acyl-CoA oxidase (*aco*) notably increased in CC treatment groups compared with the control group ( $P < 0.05$ ); furthermore, fish fed the diet with 0.04% CC had the highest expression of *ppara*, *cpt1* and *aco* ( $P < 0.05$ ) (Fig. 3(A)). The mRNA levels of sterol-regulatory element-binding protein 1 (*srebp1*) and fatty acid synthase (*fas*) in CC treatment groups dramatically decreased compared with the control group ( $P < 0.05$ ). No significant differences were observed in diacylglycerol O-acyltransferase 2 (*dgat2*) mRNA levels among dietary treatment groups ( $P > 0.05$ ) (Fig. 3(B)). The three genes, consisting of elongation of very long-chain fatty acids protein 4 (*elovl4*), *elovl5* and  $\Delta 6$  fatty acyl desaturase (*Δ6fad*), were involved in the LC-PUFA biosynthetic pathway. These genes significantly up-regulated in CC treatment groups compared with the control group ( $P < 0.05$ ), and fish fed the diet with 0.04% CC had the highest expression of *elovl4* and *elovl5* (Fig. 3(C)).

### Discussion

HFD have been widely used due to cost-effective farming and protein-sparing effects in aquaculture<sup>(1)</sup>. Suitable feed additives are effective to alleviate the adverse effects of HFD in farmed fish. The recent studies have found that dietary CC supplementation increased protein content and inhibited lipid peroxidation in the climbing perch liver<sup>(37,38)</sup>. In other fish, 50 mg/kg CC significantly improved the growth performance of tilapia fed the standard diet<sup>(20)</sup>. Fish fed the diet with 5 g/kg CC showed remarkably higher final body weight of crucian carp<sup>(21)</sup>. Previous studies have been confirmed that 18% lipid levels diet (HFD) could cause hepatic lipid deposition with lower antioxidant capacity and immunity in large yellow croaker<sup>(3,29,39)</sup>. This study found


that 0.04% CC supplementation markedly improved the growth performance of large yellow croaker fed HFD. Therefore, these suggested that CC could mitigate the adverse effects of HFD and further promote the growth of large yellow croaker.

The present study showed that lipid levels of the whole body and liver significantly decreased in 0.04% CC group, indicating that CC had a lipid-lowering effects on fish. Similar results were found in mammals that CC plays a role in lipid lowering and anti-obesity<sup>(15,40–42)</sup>. The serum lipid profiles were measured to explore effects of dietary CC on lipid metabolism of large yellow croaker. Reduced total cholesterol, TAG and LDL-cholesterol and increased HDL-cholesterol were observed in CC supplementation groups of this study, consistent with effects of CC on hypercholesterolaemia, hyperlipidaemia and non-alcoholic fatty liver<sup>(43–46)</sup>. Collectively, lipid-lowering effects of CC on large yellow croaker might be shown in serum lipid profiles and lipid content of body and liver.

To further investigate how CC regulated lipid metabolism, expression of genes related to lipid metabolism in the liver was detected. PPAR $\alpha$  has been shown to play a crucial role in reduced lipid accumulation via increasing oxidation and lipolysis of fatty acid<sup>(47–49)</sup>. The activation of PPAR $\alpha$  up-regulates expression of *aco* and *cpt1*, which are involved in oxidation of fatty acids<sup>(50,51)</sup>. In this study, mRNA expression of *ppara*, *cpt1* and *aco* significantly up-regulated in CC supplementation groups, suggesting that CC might increase oxidation of fatty acids. Similar results were found in mammals that CC promotes expression of *ppara* and further activates *cpt1* and *aco*<sup>(13,52)</sup>. SREBP positively participates in synthesising fatty acids, activating SREBP and then triggering FAS which is a critical lipogenic enzyme catalysing terminal steps in the *de novo* biogenesis of fatty acids<sup>(13,53–55)</sup>. In the present study, CC reduced expression of *srebp1* and *fas*, implying that *de novo* synthesis of fatty acids may be inhibited. Overall, CC reduced hepatic lipid deposition



## Curcumin, growth and lipid metabolism



**Fig. 3.** Effects of dietary curcumin (CC) on relative mRNA levels of genes involved in lipid metabolism pathways including (A) catabolism, (B) anabolism and (C) long-chain PUFA biosynthesis in the liver of large yellow croaker. Results are means with their standard errors ( $n$  3). <sup>a,b,c,d</sup> Mean values with the same letters were not significantly different among dietary treatments by Tukey's test ( $P > 0.05$ ). □, 0% CC; ▒, 0.02% CC; ▓, 0.04% CC; ■, 0.06% CC. *aco*, Acyl-CoA oxidase; *cpt1*, carnitine palmitoyltransferase I; *srebp1*, sterol-regulatory element-binding protein 1; *fas*, fatty acid synthase; *dgat2*, diacylglycerol O-acyltransferase 2; *elovl4*, elongation of very long-chain fatty acids protein 4; *elovl5*, elongation of very long-chain fatty acids protein 5; *Δ6fad*, Δ6 fatty acyl desaturase.

via promoting oxidation of fatty acids and decreasing *de novo* synthesis of fatty acids.

In addition to the lipid-lowering effects of CC, this study also found that CC could regulate the synthesis of PUFA in large yellow croaker. Dietary CC increased the ratio of *n*-6 PUFA: *n*-3 PUFA, while decreased SFA in the liver of large yellow croaker. These changes were probably due to improved SFA lipolysis<sup>(56)</sup>. Reduced SFA might result in increased *n*-3 PUFA and *n*-6 PUFA in the liver. In addition, CC might promote the synthesis of PUFA. In this study, CC could up-regulate expression of *elovl4*, *elovl5* and *Δ6fad* in the liver, which are speed limiting enzymes in the synthesis of PUFA<sup>(57,58)</sup>. This function of CC was firstly found in fish. In the muscle, *n*-3 PUFA and *n*-6 PUFA were dose-dependently increased by dietary CC and there were no statistical differences among treatment groups. However, it is expected that PUFA of the muscle would be remarkably increased with the farming period extending. This

finding is important because the fish muscle is an important source of PUFA for human beings.

The effects of dietary CC on alleviating liver damage and improving antioxidant capability also were investigated. aspartate transaminase and alanine transaminase are released from hepatocytes into the blood during liver injury; therefore, their activities are biomarkers of liver damage<sup>(59)</sup>. Reduced serum aspartate transaminase and alanine transaminase was observed in this study, indicating that CC was able to alleviate liver damage induced by HFD. Its protective effects on the liver have also been found on other fish<sup>(38,60,61)</sup>. In addition, previous studies have confirmed that CC could improve antioxidant capacity in mammals<sup>(11,62,63)</sup>. In this study, MDA (the biomarker of lipid peroxidation) levels were significantly decreased in CC supplementation groups, similar to results that dietary CC supplementation inhibited lipid peroxidation, and reduced MDA content in climbing perch<sup>(38)</sup>, rainbow trout<sup>(64)</sup>, crucian carps<sup>(21)</sup> and Nile



tilapia<sup>(20)</sup>. Furthermore, this study also found that dietary CC increased total antioxidant capacity and the activity of SOD and CAT, which are crucial parameters in the antioxidant system. Similar results were found in climbing perch and rainbow trout that dietary CC increased activity of SOD and/or CAT<sup>(20,37)</sup>. Collectively, these indicated that CC supplementation was likely to improve the health and function of the piscine liver through alleviating liver damage and improving antioxidant capacity. In addition, the increased *n*-6 PUFA and *n*-3 PUFA of the liver might be beneficial to the health of fish<sup>(27,65)</sup>. Therefore, the lower liver damage and higher antioxidant capacity might promote growth performance of large yellow croaker.

In conclusion, the present study showed that 0.04% CC supplementation could mitigate the adverse effects of HFD and promote growth of large yellow croaker. The positive performance of CC might attribute to its role in reducing liver lipid deposition, improving the antioxidant activity and increasing the PUFA contents. Reduced abnormal hepatic lipid deposition was probably due to increased fatty acid oxidation and decreased *de novo* synthesis of fatty acids.

### Acknowledgements

This research was supported by the National Science Fund for Distinguished Young Scholars of China (grant no. 31525024), Agriculture Research System of China (grant no. CARS-47-11) and Ten-thousand Talents Program (grant no. 2018-29).

Authors' contributions were as follows: R. J.: conceptualisation, methodology, software, validation, formal analysis, investigation, writing the original draft, review and editing of the manuscript; X. X. and X. L.: investigation, validation, and writing the original draft; K. M.: data curation, resources and supervision; Q. A.: conceptualisation, data curation, resources, review and editing of the manuscript, supervision, project administration and funding acquisition.

There are no conflicts of interest to report.

### Supplementary material

To view supplementary material for this article, please visit <https://dx.doi.org/10.1017/S0007114520004171>

### References

- Boujard T, G lineau A, Cov s D, *et al.* (2004) Regulation of feed intake, growth, nutrient and energy utilisation in European sea bass (*Dicentrarchus labrax*) fed high fat diets. *Aquaculture* **231**, 529–545.
- Du Z, Clouet P, Huang L, *et al.* (2008) Utilization of different dietary lipid sources at high level in herbivorous grass carp (*Ctenopharyngodon idella*): mechanism related to hepatic fatty acid oxidation. *Aquacult Nutr* **14**, 77–92.
- Yan J, Liao K, Wang T, *et al.* (2015) Dietary lipid levels influence lipid deposition in the liver of large yellow croaker (*Larimichthys crocea*) by regulating lipoprotein receptors, fatty acid uptake and triacylglycerol synthesis and catabolism at the transcriptional level. *PLOS ONE* **10**, e0129937.
- Aggarwal BB, Takada Y & Oommen OV (2004) From chemoprevention to chemotherapy: common targets and common goals. *Expert Opin Investig Drugs* **13**, 1327–1338.
- Aggarwal BB, Kumar A & Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res* **23**, 363–398.
- Ruby AJ, Kuttan G, Babu KD, *et al.* (1995) Anti-tumour and antioxidant activity of natural curcuminoids. *Cancer Lett* **94**, 79–83.
- Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Altern Med Rev* **14**, 141–153.
- Han S & Yang Y (2005) Antimicrobial activity of wool fabric treated with curcumin. *Dyes Pigm* **64**, 157–161.
- Nabavi SF, Daglia M, Moghaddam AH, *et al.* (2014) Curcumin and liver disease: from chemistry to medicine. *Compr Rev Food Sci Food Saf* **13**, 62–77.
- Nanji AA, Jokelainen K, Tipoe GL, *et al.* (2003) Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF- B-dependent genes. *Am J Physiol Gastrointest Liver Physiol* **284**, G321–G327.
- Aggarwal BB & Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol* **41**, 40–59.
- Soudamini K, Unnikrishnan M, Soni K, *et al.* (1992) Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. *Indian J Physiol Pharmacol* **36**, 239–239.
- Shin SK, Ha TY, McGregor RA, *et al.* (2011) Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. *Mol Nutr Food Res* **55**, 1829–1840.
- Shehzad A, Ha T, Subhan F, *et al.* (2011) New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. *Eur J Nutr* **50**, 151–161.
- Alappat L & Awad AB (2010) Curcumin and obesity: evidence and mechanisms. *Nutr Rev* **68**, 729–738.
- Bradford PG (2013) Curcumin and obesity. *Biofactors* **39**, 78–87.
- Ejaz A, Wu D, Kwan P, *et al.* (2009) Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. *J Nutr* **139**, 919–925.
- Abdel-Tawwab M & Abbass FE (2017) Turmeric powder, *Curcuma longa* L., in common carp, *Cyprinus carpio* L., diets: growth performance, innate immunity, and challenge against pathogenic *Aeromonas hydrophila* infection. *J World Aquacult Soc* **48**, 303–312.
- Adeshina I, Adewale Y & Tihamiyu L (2017) Growth performance and innate immune response of *Clarias gariepinus* infected with *Aeromonas hydrophila* fed diets fortified with *Curcuma longa* leaf. *West Afr J Appl Ecol* **25**, 87–99.
- Mahmoud HK, Al-Sagheer AA, Reda FM, *et al.* (2017) Dietary curcumin supplement influence on growth, immunity, antioxidant status, and resistance to *Aeromonas hydrophila* in *Oreochromis niloticus*. *Aquaculture* **475**, 16–23.
- Jiang J, Wu X-Y, Zhou X-Q, *et al.* (2016) Effects of dietary curcumin supplementation on growth performance, intestinal digestive enzyme activities and antioxidant capacity of crucian carp *Carassius auratus*. *Aquaculture* **463**, 174–180.
- Baba E, Acar  , Ohtaş C, *et al.* (2016) The use of *Avena sativa* extract against *Aeromonas hydrophila* and its effect on growth performance, hematological and immunological parameters in common carp (*Cyprinus carpio*). *Ital J Anim Sci* **15**, 325–333.
- Suttili FJ, Gatlin III DM, Heinzmann BM, *et al.* (2018) Plant essential oils as fish diet additives: benefits on fish health and stability in feed. *Rev Aquac* **10**, 716–726.





24. Chakraborty SB, Horn P & Hancz C (2014) Application of phytochemicals as growth-promoters and endocrine modulators in fish culture. *Rev Aquac* **6**, 1–19.
25. Liu M & De Mitcheson YS (2008) Profile of a fishery collapse: why mariculture failed to save the large yellow croaker. *Fish* **9**, 219–242.
26. Cai Z, Feng S, Xiang X, *et al.* (2016) Effects of dietary phospholipid on lipase activity, antioxidant capacity and lipid metabolism-related gene expression in large yellow croaker larvae (*Larimichthys crocea*). *Comp Biochem Physiol B Biochem Mol Biol* **201**, 46–52.
27. Zuo R, Ai Q, Mai K, *et al.* (2012) Effects of dietary docosahexaenoic to eicosapentaenoic acid ratio (DHA/EPA) on growth, nonspecific immunity, expression of some immune related genes and disease resistance of large yellow croaker (*Larimichthys crocea*) following natural infestation of parasites (*Cryptocaryon irritans*). *Aquaculture* **334**, 101–109.
28. Ji R, Xu X, Xiang X, *et al.* (2020) Regulation of adiponectin on lipid metabolism in large yellow croaker (*Larimichthys crocea*). *Biochim Biophys Acta Mol Cell Biol Lipids*, **1865**, 158711.
29. Wang T, Yan J, Xu W, *et al.* (2016) Characterization of Cyclooxygenase-2 and its induction pathways in response to high lipid diet-induced inflammation in *Larimichthys crocea*. *Sci Rep* **6**, 19921.
30. Folch J, Lees M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* **226**, 497–509.
31. Metcalfe L, Schmitz A & Pelka J (1966) Rapid preparation of fatty acid esters from lipids for gas chromatographic analysis. *Anal Chem* **38**, 514–515.
32. Ai Q, Zhao J, Mai K, *et al.* (2008) Optimal dietary lipid level for large yellow croaker (*Pseudosciaena crocea*) larvae. *Aquacult Nutr* **14**, 515–522.
33. Ji R, Li Y, Li X, *et al.* (2018) Effects of dietary tea polyphenols on growth, biochemical and antioxidant responses, fatty acid composition and expression of lipid metabolism related genes of large yellow croaker (*Larimichthys crocea*). *Aquacult Res* **49**, 1210–1218.
34. Li J, Jiang Y, Wen J, *et al.* (2009) A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. *Biomed Chromatogr* **23**, 1201–1207.
35. Li S, Monroig Ó, Wang T, *et al.* (2017) Functional characterization and differential nutritional regulation of putative Elov15 and Elov14 elongases in large yellow croaker (*Larimichthys crocea*). *Sci Rep* **7**, 2303.
36. Livak KJ & Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* **25**, 402–408.
37. Manju M, Sherin TG, Rajasekharan KN, *et al.* (2009) Curcumin analogue inhibits lipid peroxidation in a freshwater teleost, *Anabas testudineus* (Bloch)-an *in vitro* and *in vivo* study. *Fish Physiol Biochem* **35**, 413.
38. Manju M, Akbarsha MA & Oommen OV (2012) *In vivo* protective effect of dietary curcumin in fish *Anabas testudineus* (Bloch). *Fish Physiol Biochem* **38**, 309–318.
39. Yi X, Zhang F, Xu W, *et al.* (2014) Effects of dietary lipid content on growth, body composition and pigmentation of large yellow croaker *Larimichthys crocea*. *Aquaculture* **434**, 355–361.
40. Shao W, Yu Z, Chiang Y, *et al.* (2012) Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. *PLOS ONE* **7**, e28784.
41. Meydani M & Hasan ST (2010) Dietary polyphenols and obesity. *Nutrients* **2**, 737–751.
42. Yang YS, Su YF, Yang HW, *et al.* (2014) Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. *Phytother Res* **28**, 1770–1777.
43. Panahi Y, Kianpour P, Mohtashami R, *et al.* (2016) Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. *J Cardiovasc Pharmacol* **68**, 223–229.
44. Arafa HM (2005) Curcumin attenuates diet-induced hypercholesterolemia in rats. *Med Sci Monit* **11**, BR228–BR234.
45. Kim M & Kim Y (2010) Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7 $\alpha$ -hydroxylase in rats fed a high fat diet. *Nutr Res Pract* **4**, 191–195.
46. Jang E-M, Choi M-S, Jung UJ, *et al.* (2008) Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. *Metabolism* **57**, 1576–1583.
47. Guzmán M, Verme JL, Fu J, *et al.* (2004) Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor  $\alpha$  (PPAR- $\alpha$ ). *J Biol Chem* **279**, 27849–27854.
48. Badman MK, Pissios P, Kennedy AR, *et al.* (2007) Hepatic fibroblast growth factor 21 is regulated by PPAR $\alpha$  and is a key mediator of hepatic lipid metabolism in ketotic states. *Cell Metab* **5**, 426–437.
49. Yoon M (2009) The role of PPAR $\alpha$  in lipid metabolism and obesity: focusing on the effects of estrogen on PPAR $\alpha$  actions. *Pharmacol Res* **60**, 151–159.
50. Mandard S, Müller M & Kersten S (2004) Peroxisome proliferator-activated receptor  $\alpha$  target genes. *Cell Mol Life Sci CMLS* **61**, 393–416.
51. Kersten S (2014) Integrated physiology and systems biology of PPAR $\alpha$ . *Mol Metab* **3**, 354–371.
52. Um MY, Hwang KH, Ahn J, *et al.* (2013) Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. *Basic Clin Pharmacol Toxicol* **113**, 152–157.
53. You M, Fischer M, Deeg MA, *et al.* (2002) Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). *J Biol Chem* **277**, 29342–29347.
54. Menendez JA & Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat Rev Cancer* **7**, 763.
55. Horton JD, Goldstein JL & Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* **109**, 1125–1131.
56. NRC (editor) (2011) *Nutrient Requirements of Fish and Shrimp*. Washington, DC: National Academies Press.
57. Morais S, Castanheira F, Martinez-Rubio L, *et al.* (2012) Long chain polyunsaturated fatty acid synthesis in a marine vertebrate: ontogenetic and nutritional regulation of a fatty acyl desaturase with  $\Delta 4$  activity. *Biochim Biophys Acta Mol Cell Biol Lipids* **1821**, 660–671.
58. Tocher DR (2003) Metabolism and functions of lipids and fatty acids in teleost fish. *Rev Fish Sci* **11**, 107–184.
59. Kwo PY, Cohen SM & Lim JK (2017) ACG clinical guideline: evaluation of abnormal liver chemistries. *Am J Gastroenterol* **112**, 18–35.
60. Cao L, Ding W, Du J, *et al.* (2015) Effects of curcumin on antioxidant activities and cytokine production in Jian carp (*Cyprinus carpio var. Jian*) with CCl4-induced liver damage. *Fish Shellfish Immunol* **43**, 150–157.
61. Mahfouz M (2015) Ameliorative effect of curcumin on aflatoxin B1-induced changes in liver gene expression of *Oreochromis niloticus*. *Mol Biol* **49**, 275–286.
62. Wu S-J, Lin Y-H, Chu C-C, *et al.* (2008) Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects





- against CCl<sub>4</sub>-induced liver injury in rats. *J Med Food* **11**, 224–229.
63. Menon VP & Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. *Adv Exp Med Biol* **595**, 105–125.
64. Akdemir F, Orhan C, Tuzcu M, *et al.* (2017) The efficacy of dietary curcumin on growth performance, lipid peroxidation and hepatic transcription factors in rainbow trout *Oncorhynchus mykiss* (Walbaum) reared under different stocking densities. *Aquacult Res* **48**, 4012–4021.
65. Zuo R, Ai Q, Mai K, *et al.* (2012) Effects of dietary n-3 highly unsaturated fatty acids on growth, nonspecific immunity, expression of some immune related genes and disease resistance of large yellow croaker (*Larimichthys crocea*) following natural infestation of parasites (*Cryptocaryon irritans*). *Fish Shellfish Immunol* **32**, 249–258.